EA201201404A1 - Триазолы как ингибиторы кбв (кинезин-белок веретена) - Google Patents
Триазолы как ингибиторы кбв (кинезин-белок веретена)Info
- Publication number
- EA201201404A1 EA201201404A1 EA201201404A EA201201404A EA201201404A1 EA 201201404 A1 EA201201404 A1 EA 201201404A1 EA 201201404 A EA201201404 A EA 201201404A EA 201201404 A EA201201404 A EA 201201404A EA 201201404 A1 EA201201404 A1 EA 201201404A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- protein
- vereten
- kvb
- kinesin
- triazole
- Prior art date
Links
- 150000003852 triazoles Chemical class 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000010638 Kinesin Human genes 0.000 abstract 1
- 108010063296 Kinesin Proteins 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32465110P | 2010-04-15 | 2010-04-15 | |
| PCT/EP2011/055840 WO2011128381A1 (en) | 2010-04-15 | 2011-04-13 | Triazole compounds as ksp inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201201404A1 true EA201201404A1 (ru) | 2013-04-30 |
Family
ID=44009916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201201404A EA201201404A1 (ru) | 2010-04-15 | 2011-04-13 | Триазолы как ингибиторы кбв (кинезин-белок веретена) |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8546434B2 (enExample) |
| EP (1) | EP2558450A1 (enExample) |
| JP (1) | JP2013523867A (enExample) |
| KR (1) | KR20130100056A (enExample) |
| CN (1) | CN102844307A (enExample) |
| AR (1) | AR080893A1 (enExample) |
| AU (1) | AU2011239977B2 (enExample) |
| BR (1) | BR112012025879A2 (enExample) |
| CA (1) | CA2794406A1 (enExample) |
| EA (1) | EA201201404A1 (enExample) |
| MX (1) | MX2012011910A (enExample) |
| TW (1) | TW201136925A (enExample) |
| UY (1) | UY33332A (enExample) |
| WO (1) | WO2011128381A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011128388A2 (en) * | 2010-04-15 | 2011-10-20 | Novartis Ag | Oxazole and thiazole compounds as ksp inhibitors |
| EP2968591A1 (en) * | 2013-03-15 | 2016-01-20 | Novartis AG | Cell proliferation inhibitors and conjugates thereof |
| US9498540B2 (en) | 2013-03-15 | 2016-11-22 | Novartis Ag | Cell proliferation inhibitors and conjugates thereof |
| WO2016020791A1 (en) | 2014-08-05 | 2016-02-11 | Novartis Ag | Ckit antibody drug conjugates |
| CN118324664B (zh) * | 2024-03-14 | 2026-04-07 | 四川鸿日医药科技有限公司 | 一种丝氨酸衍生物的制备方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| NZ539643A (en) | 2002-10-11 | 2006-11-30 | Smithkline Beecham Corp | KSP inhibitors of formula I that can be used to treat cellular proliferative disease |
| DE602005008953D1 (de) * | 2004-05-21 | 2008-09-25 | Novartis Vaccines & Diagnostic | Substituierte chinolinderivate als inhibitoren von mitotischem kinesin |
| MXPA06014909A (es) * | 2004-06-18 | 2007-02-28 | Chiron Corp | Derivados de n-(1-(1-bencil -4-fenil-1h -imidazol -2-il)-2, 2-dimetilpropil) benzamida y compuestos relacionados como inhibidores de proteina de huso de cinesina (ksp) para el tratamiento del cancer. |
| EP1807399A2 (en) * | 2004-10-19 | 2007-07-18 | Novartis Vaccines and Diagnostics, Inc. | Indole and benzimidazole derivatives |
| JP4545196B2 (ja) * | 2005-01-19 | 2010-09-15 | メルク・シャープ・エンド・ドーム・コーポレイション | 有糸分裂キネシン阻害剤 |
| EP1868601A4 (en) * | 2005-04-07 | 2008-12-10 | Merck & Co Inc | MITOTIC KINESINE HEMMER |
| MY147188A (en) | 2005-08-09 | 2012-11-14 | Novartis Ag | Substituted imidazole compounds as ksp inhibitors |
| US7325386B2 (en) | 2005-10-17 | 2008-02-05 | Etienne Kissling | Double action vertical form-fill-seal apparatus |
| MX2009005071A (es) * | 2006-11-13 | 2009-05-25 | Novartis Ag | Compuestos de pirazol y triazol sustituidos como inhibidores de ksp. |
| GEP20125415B (en) | 2007-01-05 | 2012-03-12 | Novartis Ag | Imidazole derivatives as kinesin spindle protein inhibitors (eg-5) |
| WO2011128388A2 (en) | 2010-04-15 | 2011-10-20 | Novartis Ag | Oxazole and thiazole compounds as ksp inhibitors |
-
2011
- 2011-04-13 EP EP11715682A patent/EP2558450A1/en active Pending
- 2011-04-13 KR KR1020127029781A patent/KR20130100056A/ko not_active Withdrawn
- 2011-04-13 AU AU2011239977A patent/AU2011239977B2/en not_active Expired - Fee Related
- 2011-04-13 CN CN2011800184156A patent/CN102844307A/zh active Pending
- 2011-04-13 JP JP2013504265A patent/JP2013523867A/ja active Pending
- 2011-04-13 AR ARP110101254A patent/AR080893A1/es unknown
- 2011-04-13 BR BR112012025879A patent/BR112012025879A2/pt not_active IP Right Cessation
- 2011-04-13 CA CA2794406A patent/CA2794406A1/en not_active Abandoned
- 2011-04-13 US US13/085,746 patent/US8546434B2/en not_active Expired - Fee Related
- 2011-04-13 WO PCT/EP2011/055840 patent/WO2011128381A1/en not_active Ceased
- 2011-04-13 MX MX2012011910A patent/MX2012011910A/es not_active Application Discontinuation
- 2011-04-13 EA EA201201404A patent/EA201201404A1/ru unknown
- 2011-04-14 TW TW100113030A patent/TW201136925A/zh unknown
- 2011-04-14 UY UY0001033332A patent/UY33332A/es not_active Application Discontinuation
-
2013
- 2013-08-28 US US14/012,167 patent/US20140056880A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011239977B2 (en) | 2014-11-27 |
| MX2012011910A (es) | 2012-11-29 |
| AR080893A1 (es) | 2012-05-16 |
| CA2794406A1 (en) | 2011-10-20 |
| AU2011239977A1 (en) | 2012-11-01 |
| US20110256128A1 (en) | 2011-10-20 |
| UY33332A (es) | 2011-12-01 |
| WO2011128381A1 (en) | 2011-10-20 |
| US8546434B2 (en) | 2013-10-01 |
| CN102844307A (zh) | 2012-12-26 |
| JP2013523867A (ja) | 2013-06-17 |
| US20140056880A1 (en) | 2014-02-27 |
| BR112012025879A2 (pt) | 2017-11-21 |
| TW201136925A (en) | 2011-11-01 |
| EP2558450A1 (en) | 2013-02-20 |
| KR20130100056A (ko) | 2013-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201290919A1 (ru) | Индазольные соединения и их применение | |
| EA201170061A1 (ru) | Новые производные фенилимидазола в качестве ингибиторов фермента pde10a | |
| EA201001094A1 (ru) | Производные индазола | |
| EA201291356A1 (ru) | Пиперидиноновые производные как ингибиторы mdm2 для лечения рака | |
| EA201490418A1 (ru) | Новые макроциклические соединения в качестве ингибиторов фактора xia | |
| EA201101583A1 (ru) | Ингибиторы pi3 киназы или mtor | |
| EA201300860A1 (ru) | Кристаллические трипептидные ингибиторы эпоксикетон-протеазы | |
| EA201170670A1 (ru) | Аминотетрагидропираны в качестве ингибиторов дипептидилпептидазы-iv для лечения или предупреждения диабета | |
| EA201100750A1 (ru) | Замещенные диоксопиперидинилфталимидные производные | |
| UA108369C2 (uk) | Піролопіримідини як інгібітори cdk4/6 | |
| EA201501060A1 (ru) | Комбинации активных соединений, содержащие производное соединение (тио)карбоксамида и фунгицидное соединение | |
| MX352672B (es) | Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer. | |
| EA201692166A1 (ru) | Гетероциклические ингибиторы глютаминазы | |
| EA201101507A1 (ru) | Способы лечения солидных опухолей | |
| EA200970542A1 (ru) | ИНГИБИТОРЫ ДЕЙСТВИЯ Akt | |
| EA201290518A1 (ru) | Производные 2-арилимидазола в качестве ингибиторов фермента pde10a | |
| EA201692506A3 (ru) | Ингибиторы репликации вирусов гриппа | |
| EA201290516A1 (ru) | Гетероароматические производные соединения фенилимидазола в качестве ингибиторов фермента pde10a | |
| EA201490103A1 (ru) | Гидроксиметиларилзамещенные пирролотриазины в качестве ингибиторов alk1 | |
| WO2011127333A3 (en) | Compounds for treating disease, for administering, and for pharmaceutical compositions | |
| EA201101533A1 (ru) | Гетероциклические соединения в качестве ингибиторов mek | |
| EA201390741A1 (ru) | Производные имидазола в качестве ингибиторов фермента pde10a | |
| EA200970512A1 (ru) | Лечение по поводу множественной миеломы | |
| EA201001196A1 (ru) | Соединения 4-пиридинона и их применение для лечения рака | |
| EA201290517A1 (ru) | Гетероароматические арилтриазольные производные в качестве ингибиторов фермента pde10a |